Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ImmunoPrecise Antibodies

TSXV:IPA
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IPA
TSXV
CA$47M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
IPA Share Price and Events
7 Day Returns
9.5%
TSXV:IPA
10.2%
North America Life Sciences
11.7%
CA Market
1 Year Returns
-4.2%
TSXV:IPA
-8.4%
North America Life Sciences
-26%
CA Market
IPA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ImmunoPrecise Antibodies (IPA) 9.5% -1.4% 21.1% -4.2% -43.4% -
North America Life Sciences 10.2% -8.9% -18.1% -8.4% 56% 79.4%
CA Market 11.7% -21.9% -26.6% -26% -23.6% -17.8%
1 Year Return vs Industry and Market
  • IPA outperformed the Life Sciences industry which returned -8.4% over the past year.
  • IPA outperformed the Market in Canada which returned -26% over the past year.
Price Volatility
IPA
Industry
5yr Volatility vs Market

Value

 Is ImmunoPrecise Antibodies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for ImmunoPrecise Antibodies. This is due to cash flow or dividend data being unavailable. The share price is CA$0.69.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ImmunoPrecise Antibodies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ImmunoPrecise Antibodies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
TSXV:IPA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2020-01-31) in CAD CA$-0.12
TSXV:IPA Share Price ** TSXV (2020-03-26) in CAD CA$0.69
North America Life Sciences Industry PE Ratio Median Figure of 20 Publicly-Listed Life Sciences Companies 29.35x
Canada Market PE Ratio Median Figure of 498 Publicly-Listed Companies 10.58x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ImmunoPrecise Antibodies.

TSXV:IPA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:IPA Share Price ÷ EPS (both in CAD)

= 0.69 ÷ -0.12

-5.97x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmunoPrecise Antibodies is loss making, we can't compare its value to the North America Life Sciences industry average.
  • ImmunoPrecise Antibodies is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does ImmunoPrecise Antibodies's expected growth come at a high price?
Raw Data
TSXV:IPA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.97x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
North America Life Sciences Industry PEG Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 2.05x
Canada Market PEG Ratio Median Figure of 235 Publicly-Listed Companies 0.71x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ImmunoPrecise Antibodies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ImmunoPrecise Antibodies's assets?
Raw Data
TSXV:IPA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2020-01-31) in CAD CA$0.21
TSXV:IPA Share Price * TSXV (2020-03-26) in CAD CA$0.69
North America Life Sciences Industry PB Ratio Median Figure of 42 Publicly-Listed Life Sciences Companies 4.36x
Canada Market PB Ratio Median Figure of 2,349 Publicly-Listed Companies 0.99x
TSXV:IPA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:IPA Share Price ÷ Book Value per Share (both in CAD)

= 0.69 ÷ 0.21

3.25x

* Primary Listing of ImmunoPrecise Antibodies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ImmunoPrecise Antibodies is good value based on assets compared to the North America Life Sciences industry average.
X
Value checks
We assess ImmunoPrecise Antibodies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. ImmunoPrecise Antibodies has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is ImmunoPrecise Antibodies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ImmunoPrecise Antibodies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.8%
Expected Life Sciences industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ImmunoPrecise Antibodies expected to grow at an attractive rate?
  • Unable to compare ImmunoPrecise Antibodies's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare ImmunoPrecise Antibodies's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare ImmunoPrecise Antibodies's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
TSXV:IPA Future Growth Rates Data Sources
Data Point Source Value (per year)
North America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 16.8%
North America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 6.7%
Canada Market Earnings Growth Rate Market Cap Weighted Average 7.5%
Canada Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
TSXV:IPA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
TSXV:IPA Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
TSXV:IPA Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2020-01-31 13 -3 -8
2019-10-31 11 -3 -8
2019-07-31 11 -3 -9
2019-04-30 11 -3 -8
2019-01-31 10 -3 -6
2018-10-31 9 -3 -6
2018-07-31 8 -2 -5
2018-04-30 5 -3 -5
2018-01-31 4 -3 -4
2017-10-31 3 -3 -7
2017-07-31 2 -2 -6
2017-04-30 3 -1 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if ImmunoPrecise Antibodies is high growth as no earnings estimate data is available.
  • Unable to determine if ImmunoPrecise Antibodies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
TSXV:IPA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from ImmunoPrecise Antibodies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:IPA Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
TSXV:IPA Past Financials Data
Date (Data in CAD Millions) EPS *
2020-01-31 -0.12
2019-10-31 -0.12
2019-07-31 -0.13
2019-04-30 -0.12
2019-01-31 -0.10
2018-10-31 -0.11
2018-07-31 -0.11
2018-04-30 -0.11
2018-01-31 -0.09
2017-10-31 -0.18
2017-07-31 -0.22
2017-04-30 -0.27

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ImmunoPrecise Antibodies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of IPA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. ImmunoPrecise Antibodies's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. ImmunoPrecise Antibodies's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess ImmunoPrecise Antibodies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the North America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the North America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ImmunoPrecise Antibodies has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has ImmunoPrecise Antibodies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ImmunoPrecise Antibodies's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ImmunoPrecise Antibodies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ImmunoPrecise Antibodies's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ImmunoPrecise Antibodies's 1-year growth to the North America Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
ImmunoPrecise Antibodies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ImmunoPrecise Antibodies Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

TSXV:IPA Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2020-01-31 12.55 -7.84 8.56 0.86
2019-10-31 11.22 -8.41 9.15 1.05
2019-07-31 10.77 -8.53 9.13 0.62
2019-04-30 10.93 -7.62 9.12 0.49
2019-01-31 10.10 -5.97 8.70 0.68
2018-10-31 9.12 -6.00 8.84 0.34
2018-07-31 7.72 -5.42 7.83 0.43
2018-04-30 5.44 -5.17 6.46 0.51
2018-01-31 4.23 -4.17 5.23 0.78
2017-10-31 3.01 -7.40 3.64 0.88
2017-07-31 2.49 -6.39 2.45 0.71
2017-04-30 2.63 -5.38 2.05 0.66
2017-01-31 2.73 -3.83 1.14 0.13
2016-10-31 2.63 0.55 0.77 0.19
2016-07-31 2.26 0.42 1.02 0.31
2016-04-30 1.90 0.15 0.99 0.30
2015-04-30 1.76 0.29 0.84 0.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ImmunoPrecise Antibodies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ImmunoPrecise Antibodies has efficiently used its assets last year compared to the North America Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ImmunoPrecise Antibodies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ImmunoPrecise Antibodies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ImmunoPrecise Antibodies has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is ImmunoPrecise Antibodies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ImmunoPrecise Antibodies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ImmunoPrecise Antibodies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ImmunoPrecise Antibodies's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ImmunoPrecise Antibodies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ImmunoPrecise Antibodies Company Filings, last reported 1 month ago.

TSXV:IPA Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2020-01-31 14.45 2.80 1.94
2019-10-31 14.60 2.81 2.96
2019-07-31 15.70 2.90 4.95
2019-04-30 18.07 2.82 5.47
2019-01-31 19.86 2.75 7.12
2018-10-31 20.64 2.72 8.83
2018-07-31 12.25 4.05 2.36
2018-04-30 12.70 3.78 1.81
2018-01-31 10.14 0.00 1.84
2017-10-31 10.59 0.00 2.26
2017-07-31 2.47 0.00 1.27
2017-04-30 3.09 0.00 2.58
2017-01-31 3.83 0.09 3.48
2016-10-31 1.08 0.09 0.57
2016-07-31 0.97 0.00 0.46
2016-04-30 0.91 0.00 0.56
2015-04-30 0.82 0.03 0.36
  • ImmunoPrecise Antibodies's level of debt (19.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if ImmunoPrecise Antibodies's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ImmunoPrecise Antibodies has less than a year of cash runway based on current free cash flow.
  • ImmunoPrecise Antibodies has less than a year of cash runway if free cash flow continues to grow at historical rates of 46.9% each year.
X
Financial health checks
We assess ImmunoPrecise Antibodies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ImmunoPrecise Antibodies has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is ImmunoPrecise Antibodies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ImmunoPrecise Antibodies dividends.
If you bought CA$2,000 of ImmunoPrecise Antibodies shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ImmunoPrecise Antibodies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ImmunoPrecise Antibodies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
TSXV:IPA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.5%
Canada Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 4.9%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.3%
Canada Bottom 25% Dividend Yield 25th Percentile 2.7%
Canada Top 25% Dividend Yield 75th Percentile 8.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

TSXV:IPA Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ImmunoPrecise Antibodies has not reported any payouts.
  • Unable to verify if ImmunoPrecise Antibodies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ImmunoPrecise Antibodies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ImmunoPrecise Antibodies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ImmunoPrecise Antibodies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.3%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ImmunoPrecise Antibodies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ImmunoPrecise Antibodies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of ImmunoPrecise Antibodies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jennifer Bath
COMPENSATION CA$537,682
TENURE AS CEO 2 years
CEO Bio

Dr. Jennifer Bath has been the Chief Executive Officer and President of ImmunoPrecise Antibodies Ltd. since February 21, 2018. Dr. Bath served as the Global Director of Client Relations at Aldevron, LLC, where she held both strategic and technical roles. She headed the global sales and client relations teams, and defined business strategies by applying knowledge based on science, technology and the market. In addition, she served as a key technical specialist, particularly for therapeutic antibody discovery, and was responsible for growth and retention of the company's client base. Dr. Bath has been a Director at ImmunoPrecise Antibodies Ltd., since May 2018. Dr. Bath served in many industry leadership roles, contributed to the Economic Development Corporation's Strategic Planning Initiatives, advised biotechnology and pharmaceutical companies on strategic and operational business practices, and facilitated workshops in technology entrepreneurship. She has strong relationships with leaders in the fields of therapeutics and vaccinology and has fostered many collaborative developments and partnerships in discovery. She began her career in academia and moved into industry after serving for 15 years as Associate Professor of Cellular and Molecular Biology at Concordia College, Moorhead, Minnesota. She was the Founder and Executive Director of the Concordia College Global Vaccine Institute, the mission of which is to prevent and treat neglected tropical diseases. Dr. Bath has broad experience in vaccine and therapeutic design, development and testing. Dr. Jennifer Bath holds a Ph.D. in Cellular and Molecular biology from North Dakota State University, and a Bachelor's degree in Biology with an emphasis on human genetics from the University of Kansas.

CEO Compensation
  • Jennifer's compensation has increased whilst company is loss making.
  • Jennifer's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the ImmunoPrecise Antibodies management team in years:

2
Average Tenure
  • The average tenure for the ImmunoPrecise Antibodies management team is less than 2 years, this suggests a new team.
Management Team

Jim Kuo

TITLE
Independent Chairman of the Board
AGE
54
TENURE
2.3 yrs

Jennifer Bath

TITLE
CEO, President & Director
COMPENSATION
CA$538K
TENURE
2 yrs

Lisa Helbling

TITLE
Chief Financial Officer
COMPENSATION
CA$116K
TENURE
1.2 yrs

Chip Wheelock

TITLE
Chief Technology Officer
COMPENSATION
CA$332K
TENURE
1.9 yrs

Jason Orloske

TITLE
Vice President of Operations
COMPENSATION
CA$75K
TENURE
1.3 yrs

David Orton

TITLE
Chief Operating Officer
TENURE
3 yrs

Lauren Smith

TITLE
Vice President of Marketing and Sales
TENURE
2.9 yrs

Stefan Lang

TITLE
Chief Business Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the ImmunoPrecise Antibodies board of directors in years:

2
Average Tenure
55
Average Age
  • The average tenure for the ImmunoPrecise Antibodies board of directors is less than 3 years, this suggests a new board.
Board of Directors

Jennifer Bath

TITLE
CEO, President & Director
COMPENSATION
CA$538K
TENURE
1.8 yrs

Robert Beecroft

TITLE
Founder & Independent Director
COMPENSATION
CA$21K
TENURE
24.8 yrs

Jim Kuo

TITLE
Independent Chairman of the Board
AGE
54
TENURE
3.3 yrs

Greg Smith

TITLE
Independent Director
AGE
52
TENURE
3.7 yrs

Guy Champagne

TITLE
Member of Advisory Board
COMPENSATION
CA$55K
AGE
63
TENURE
1.6 yrs

Robert Burke

TITLE
Independent Director
TENURE
2.3 yrs

Paul Andreola

TITLE
Independent Director
AGE
55
TENURE
1.3 yrs

Brian Lundstrom

TITLE
Additional Independent Director
AGE
56
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by ImmunoPrecise Antibodies individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
18. Nov 19 Buy Paul Andreola Individual 18. Nov 19 18. Nov 19 8,500 CA$0.59 CA$5,015
20. Jan 20 Buy Jennifer Bath Individual 17. Jan 20 17. Jan 20 9,000 CA$0.63 CA$5,670
16. Jan 20 Buy Brian Lundstrom Individual 16. Jan 20 16. Jan 20 69,000 CA$0.57 CA$39,599
23. Dec 19 Buy Paul Andreola Individual 23. Dec 19 23. Dec 19 9,000 CA$0.53 CA$4,770
20. Dec 19 Buy Lisa Helbling Individual 19. Dec 19 19. Dec 19 5,000 CA$0.54 CA$2,698
07. Nov 19 Buy Paul Andreola Individual 07. Nov 19 07. Nov 19 7,500 CA$0.57 CA$4,275
19. Nov 19 Buy Paul Andreola Individual 19. Nov 19 19. Nov 19 10,000 CA$0.59 CA$5,900
15. Nov 19 Buy Stefan Lang Individual 14. Nov 19 14. Nov 19 7,000 CA$0.61 CA$4,270
13. Nov 19 Buy Lisa Helbling Individual 13. Nov 19 13. Nov 19 5,000 CA$0.46 CA$2,289
13. Nov 19 Buy Paul Andreola Individual 13. Nov 19 13. Nov 19 10,000 CA$0.60 CA$6,000
14. Nov 19 Buy Paul Andreola Individual 14. Nov 19 14. Nov 19 10,000 CA$0.60 CA$6,000
12. Nov 19 Buy Paul Andreola Individual 11. Nov 19 11. Nov 19 10,000 CA$0.57 CA$5,700
28. Oct 19 Buy Martin Hessing Individual 28. Oct 19 28. Oct 19 5,000 CA$0.54 CA$2,700
09. Oct 19 Buy Paul Andreola Individual 09. Oct 19 09. Oct 19 10,000 CA$0.47 CA$4,650
16. Oct 19 Buy Martin Hessing Individual 16. Oct 19 16. Oct 19 5,000 CA$0.50 CA$2,500
10. Oct 19 Buy Paul Andreola Individual 10. Oct 19 10. Oct 19 100,000 CA$0.45 CA$45,000
03. Oct 19 Buy Martin Hessing Individual 03. Oct 19 03. Oct 19 5,000 CA$0.52 CA$2,565
01. Oct 19 Buy Paul Andreola Individual 01. Oct 19 01. Oct 19 10,000 CA$0.47 CA$4,700
20. Sep 19 Buy Martin Hessing Individual 19. Sep 19 19. Sep 19 5,000 CA$0.60 CA$3,000
12. Sep 19 Buy Jennifer Bath Individual 10. Sep 19 10. Sep 19 6,975 CA$0.58 CA$4,016
17. Jul 19 Buy Jennifer Bath Individual 17. Jul 19 17. Jul 19 5,000 CA$0.66 CA$3,264
31. May 19 Buy Paul Andreola Individual 30. May 19 30. May 19 10,000 CA$0.69 CA$6,900
X
Management checks
We assess ImmunoPrecise Antibodies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ImmunoPrecise Antibodies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

ImmunoPrecise Antibodies Ltd. (CVE:IPA): What Does Its Beta Value Mean For Your Portfolio?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … This is reasonably close to the market beta of 1, so the stock has in the past displayed similar levels of volatility to the overall market. … What this means for you: ImmunoPrecise Antibodies has a beta value quite close to that of the overall market.

Simply Wall St -

What Type Of Shareholder Owns ImmunoPrecise Antibodies Ltd.'s (CVE:IPA)?

Insider Ownership Of ImmunoPrecise Antibodies The definition of company insiders can be subjective, and does vary between jurisdictions. … General Public Ownership The general public, who are mostly retail investors, collectively hold 66% of ImmunoPrecise Antibodies shares. … Public Company Ownership We can see that public companies hold 3.8%, of the IPA shares on issue.

Simply Wall St -

Did ImmunoPrecise Antibodies Ltd. (CVE:IPA) Insiders Sell Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in ImmunoPrecise Antibodies Ltd. … See our latest analysis for ImmunoPrecise Antibodies ImmunoPrecise Antibodies Insider Transactions Over The Last Year In the last twelve months, the biggest single sale by an insider was when the Member of Advisory Board, Guy Champagne, sold CA$126k worth of shares at a price of CA$1.09 per share. … Does ImmunoPrecise Antibodies Boast High Insider Ownership?

Simply Wall St -

Did Changing Sentiment Drive ImmunoPrecise Antibodies's (CVE:IPA) Share Price Down By 12%?

ImmunoPrecise Antibodies isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth. … In the last twelve months, ImmunoPrecise Antibodies increased its revenue by 139%.

Simply Wall St -

What Kind Of Shareholder Appears On The ImmunoPrecise Antibodies Ltd.'s (CVE:IPA) Shareholder Register?

So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at our data on the ownership groups (below), it's seems that. … We can zoom in on the different ownership groups, to learn more about IPA

Simply Wall St -

What Does ImmunoPrecise Antibodies Ltd's (CVE:IPA) Ownership Structure Look Like?

I am going to take a deep dive into ImmunoPrecise Antibodies Ltd’s (CVE:IPA) most recent ownership structure, not a frequent subject of discussion among individual investors. … Ownership structure of a company has been found to affect share performance over time. … Therefore, it is beneficial for us to examine IPA's ownership structure in more detail.

Simply Wall St -

What Can We Expect for ImmunoPrecise Antibodies Ltd (TSXV:IPA) Moving Forward?

TSXV:IPA Past Future Earnings Nov 6th 17 Companies operating in the life sciences sector are confronted with ways to improve R&D productivity, increase the efficiency of its operations, rationalise spending on sales and marketing and enhance financial performance. … If your initial investment thesis is around the growth prospects of IPA, there are other life sciences companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its life sciences peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Company Info

Description

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; and modeling, design, and manufacturing of custom antigen. The company also offers phage-display antibody platforms that generates monoclonal antibodies in a diverse range of species against complex protein structures; Genetic Immunization Platform; and DeepDisplay, a service offering in therapeutic discovery to select rare, fully human antibodies. The company was incorporated in 1983 and is headquartered in Fargo, North Dakota.

Details
Name: ImmunoPrecise Antibodies Ltd.
IPA
Exchange: TSXV
Founded: 1983
CA$46,916,167
67,994,445
Website: http://www.immunoprecise.com
Address: ImmunoPrecise Antibodies Ltd.
4837 Amber Valley Parkway,
Suite 11,
Fargo,
North Dakota, 58104,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV IPA Common Shares TSX Venture Exchange CA CAD 30. Dec 2016
OTCPK IPAT.F Common Shares Pink Sheets LLC US USD 30. Dec 2016
DB TQB2 Common Shares Deutsche Boerse AG DE EUR 30. Dec 2016
Number of employees
Current staff
Staff numbers
0
ImmunoPrecise Antibodies employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 04:21
End of day share price update: 2020/03/26 00:00
Last estimates confirmation: 2019/08/28
Last earnings filing: 2020/03/10
Last earnings reported: 2020/01/31
Last annual earnings reported: 2019/04/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.